Menu
Search
|

Menu

Close
X

CRISPR Therapeutics AG CRSP.OQ (NASDAQ Stock Exchange Global Market)

36.13 USD
+1.37 (+3.94%)
As of 3:33 PM EST
chart
Previous Close 34.76
Open 34.34
Volume 216,291
3m Avg Volume 279,407
Today’s High 36.94
Today’s Low 34.34
52 Week High 73.90
52 Week Low 17.32
Shares Outstanding (mil) 51.90
Market Capitalization (mil) 1,893.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.36 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
41
FY16
5
FY15
0
EPS (USD)
FY18
-2.506
FY17
-1.557
FY16
0.382
FY15
-0.642
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
53.58
22.95
Price to Book (MRQ)
vs sector
4.51
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.00
15.47
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-29.32
13.00
Return on Equity (TTM)
vs sector
-37.21
14.69

EXECUTIVE LEADERSHIP

Rodger Novak
Chairman of the Board of Directors, President, Founder, Since 2017
Salary: $356,242.00
Bonus: $118,424.00
Samarth Kulkarni
Chief Executive Officer, Director, Since 2018
Salary: $145,833.00
Bonus: $43,750.00
Kala Subramanian
Senior Vice President - Strategic Development and Operations, Since 2016
Salary: --
Bonus: --
Megan Wherry Menner
Senior Vice President of Human Resources, Since
Salary: --
Bonus: --
Sven Lundberg
Chief Scientific Officer, Since 2015
Salary: $302,605.00
Bonus: $90,928.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Baarerstrasse 14
ZUG   ZUG   6300

Phone: +4141.5613277

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

SPONSORED STORIES